A new study has reported that women who experience symptoms such as hot flashes at menopause have a lower risk of breast cancer than women who do not experience menopausal symptoms. Previous studies have reported that women with menopausal symptoms have lower estrogen levels as a result of going through menopause compared with women who do not.
Given the central role of hormones in the development of breast cancer, a link between menopausal symptoms such as hot flashes and breast cancer risk is plausible. The study included 1,437 postmenopausal Seattle-area women, of whom 988 had previously been diagnosed with breast cancer and 449 served as cancer-free controls. The women were surveyed about perimenopausal and menopausal symptoms, including hot flashes, night sweats, vaginal dryness, irregular or heavy menstrual bleeding, insomnia, depression and anxiety.
The associations between these symptoms and risks of different histologic types of breast cancer among postmenopausal women were examined.
Women who experienced menopausal symptoms were found to have a 50% lower risk of both ductal and lobular breast cancer than women who experienced no symptoms. The association between such symptoms and decreased cancer risk held even after accounting for other factors known to boost breast cancer risk, such as use of hormone replacement therapy (HRT), obesity and age at menopause.
The greater the intensity of hot flashes, the lower the risk of breast cancer. In a separate interview, senior author Christopher I. Li, a breast cancer epidemiologist in the Hutchinson Center’s Public Health Sciences Division, said that “women who experienced more intense hot flushes - the kind that woke them up at night - had a particularly low risk of breast cancer.”
Selected breast cancer studies
Abstract B99: Hot flashes, hormone therapy, and breast cancer risk: The Women's Health Initiative Clinical Trials
Farhat GN, LaCroix A, Grady D, Chlebowski R, Vitolins M, Manson J, et al. Abstract B99: Hot flashes, hormone therapy, and breast cancer risk: The Women's Health Initiative Clinical Trials. Epidemiology and Lifestyle Factors. American Association for Cancer Research; 2010; 10.1158/1940-6207.prev-10-b99
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. BMJ; 2010; 340:c693-c693 10.1136/bmj.c693
Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors
Su HI, Sammel MD, Springer E, Freeman EW, DeMichele A, Mao JJ. Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 124:205-211 10.1007/s10549-010-0802-6
A dietary supplement for female sexual dysfunction, Avlimil, stimulates the growth of estrogen-dependent breast tumors (MCF-7) implanted in ovariectomized athymic nude mice
Ju YH, Doerge DR, Helferich WG. A dietary supplement for female sexual dysfunction, Avlimil, stimulates the growth of estrogen-dependent breast tumors (MCF-7) implanted in ovariectomized athymic nude mice. Food and Chemical Toxicology. Elsevier BV; 2008; 46:310-320 10.1016/j.fct.2007.08.006